Literature DB >> 16033743

Uveal and conjunctival malignant melanoma in Denmark, 1943-97: incidence and validation study.

P Isager1, A Østerlind, G Engholm, S Heegaard, J Lindegaard, J Overgaard, H H Storm.   

Abstract

PURPOSE: To study the incidence of malignant melanoma in the ocular region in Denmark during the period 1943-97.
METHODS: The patients were mainly identified through the Danish Cancer Registry. Age-period-cohort modelling of the incidence rates was done based on age at diagnosis, calendar period and birth cohort in 5-year groups and for each gender.
RESULTS: The age-standardized incidence of malignant melanoma in the ocular region was 0.78 for men (N = 1327) and 0.65 for women (N = 1242) per 100,000 person-years. Calendar period and birth cohort had no effect on the incidence in the ocular region or in the topography subgroups choroid/ciliary body and conjunctiva. However, the incidence increased with birth cohort for iris melanomas.
CONCLUSIONS: The incidence of malignant melanoma in the ocular region was stable in contrast to a major increase in cutaneous melanoma in Denmark during the period 1943-97. The incidence of iris melanomas increased substantially, whereas the rate was stable for choroid/ciliary body and conjunctival melanomas.

Entities:  

Mesh:

Year:  2005        PMID: 16033743     DOI: 10.1080/09286580591000836

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  21 in total

1.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

Review 2.  Conjunctival Melanoma - Epidemiological Trends and Features.

Authors:  Snježana Kaštelan; Antonela Gverović Antunica; Lidija Beketić Orešković; Jasminka Salopek Rabatić; Boris Kasun; Ivana Bakija
Journal:  Pathol Oncol Res       Date:  2018-05-25       Impact factor: 3.201

Review 3.  Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.

Authors:  Joel M Mor; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2016-12-08

Review 4.  Conjunctival melanoma and melanocytic intra-epithelial neoplasia.

Authors:  N Kenawy; S L Lake; S E Coupland; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

5.  Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.

Authors:  Jonathan E Lu; Jessica R Chang; Jesse L Berry; Gino K In; Sandy Zhang-Nunes
Journal:  Int Ophthalmol Clin       Date:  2020

6.  Incidence and Survival of Patients With Conjunctival Melanoma in Europe.

Authors:  Gianni Virgili; Mariacristina Parravano; Gemma Gatta; Riccardo Capocaccia; Cinzia Mazzini; Sandra Mallone; Laura Botta
Journal:  JAMA Ophthalmol       Date:  2020-06-01       Impact factor: 7.389

7.  Gamma Knife Radiosurgery for Uveal Melanoma: A Retrospective Review of Clinical Complications in a Tertiary Referral Center.

Authors:  Giulio Maria Modorati; Roi Dagan; Lauge Hjorth Mikkelsen; Simon Andreasen; Alfio Ferlito; Francesco Bandello
Journal:  Ocul Oncol Pathol       Date:  2019-09-03

8.  Five Decades of Enucleations for Uveal Melanoma in One Center: More Tumors with High Risk Factors, No Improvement in Survival over Time.

Authors:  Christine D M Roelofsen; Annemijn P A Wierenga; Sjoerd van Duinen; Robert M Verdijk; Jaco Bleeker; Marina Marinkovic; Gregorius P M Luyten; Martine J Jager
Journal:  Ocul Oncol Pathol       Date:  2020-12-15

9.  Conjunctival melanoma: a review of conceptual and treatment advances.

Authors:  Li-Anne Lim; Michele C Madigan; R Max Conway
Journal:  Clin Ophthalmol       Date:  2013-03-13

10.  A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers.

Authors:  Lauren G Aoude; Karin Wadt; Anders Bojesen; Dorthe Crüger; Ake Borg; Jeffrey M Trent; Kevin M Brown; Anne-Marie Gerdes; Göran Jönsson; Nicholas K Hayward
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.